Novel medicines targeting infectious diseases

AN2 Therapeutics is leveraging a unique boron chemistry platform to develop novel therapies aimed at treating infectious diseases and oncology. Their approach focuses on creating boron-based compounds that exhibit the potential to be best-in-class therapeutics. The company has a pipeline that includes promising candidates such as AN2-502998, which is under development for chronic Trypanosoma cruzi infection, known as Chagas disease. This compound has shown curative activity in preclinical studies across multiple species, including non-human primates, making it a significant advancement in the treatment of a disease that affects millions globally. Additionally, AN2 is exploring epetraborole, a small molecule inhibitor targeting bacterial leucyl-tRNA synthetase, which has demonstrated efficacy against various infectious diseases, including melioidosis and non-tuberculous mycobacterial lung disease.

The boron chemistry utilized by AN2 Therapeutics allows for the creation of highly selective inhibitors that can effectively target biological pathways often resistant to traditional drug discovery methods. This innovative approach not only enhances the understanding of boron’s interactions with biological targets but also facilitates the design of compounds with optimized properties such as solubility and metabolic stability. By advancing their boron-based drug discovery platform, AN2 Therapeutics aims to address significant unmet medical needs in the treatment of infectious diseases, thereby contributing to global health initiatives and improving patient outcomes.

United States

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.

Infectious Diseases

Lung Diseases

AN2 Therapeutics

Bacterial infection

Melioidosis

Epetraborole

Chagas disease

AN2-502998

Lung disease

Mycobacterium avium complex lung disease

<p class="font_8">We are developing oral epetraborole for the treatment of &nbsp;non-tuberculous mycobacterial, or NTM, lung disease. Epetraborole is a &nbsp;boron-containing, orally-available, small molecule inhibitor of &nbsp;bacterial leucyl-tRNA synthetase, or LeuRS, an enzyme that catalyzes the &nbsp;attachment of leucine to transfer RNA, or tRNA, molecules, an essential &nbsp;step in protein synthesis. Epetraborole forms a complex with a tRNALeu molecule, trapping the terminal ribonucleotide of tRNALeu in the editing site of the enzyme, which prevents the synthetic site from attaching leucine to tRNALeu thus shutting down tRNA leucylation and leading to a block in protein synthesis.</p>

AN2 Therapeutics

Company Details